ALX Oncology
Dr. Yeong-Liang Lin has served as the Senior Vice President, Drug Safety and Pharmacovigilance since June 2022. From June 2020 to June 2022, he served as Vice President, Drug Safety and Pharmacovigilance at Vir Biotechnology. Previously, Dr. Lin held roles of increasing responsibility in drug safety at BeiGene, Genentech, Johnson & Johnson and the Center for Drug Evaluation in Taiwan. He completed his postgraduate medical training at the National Taiwan University Hospital. Dr. Lin holds an M.D. from National Taiwan University and an M.S. in Epidemiology from Harvard University.
This person is not in any teams
This person is not in any offices
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.